MannKind Licenses Inhalation Tech to Rose Pharma for Weight Management GLP-1 Drug
Event summary
- MannKind licenses its Technosphere® inhalation tech to Rose Pharma for ROSE-010, a rapid-acting GLP-1 drug for weight management.
- Deal includes equity stake and royalties for MannKind, which will support Phase 1b clinical development.
- ROSE-010 has shown promise in reducing caloric intake and weight loss in prior trials.
- Rose Pharma retains clinical and commercialization responsibilities.
- Agreement announced on September 9, 2026.
The big picture
The deal underscores the growing interest in inhaled drug delivery for weight management, a market dominated by injectable GLP-1 therapies. MannKind’s Technosphere® platform expands its reach beyond diabetes into obesity and irritable bowel syndrome (IBS), while Rose Pharma gains a strategic partner to de-risk development. The collaboration comes as patient preference surveys highlight demand for more flexible GLP-1 treatment options.
What we're watching
- Clinical Progress
- Whether ROSE-010 can replicate prior Phase 2a results in the upcoming Phase 1b study.
- Market Differentiation
- How the rapid-acting, short-duration profile of ROSE-010 positions it against existing GLP-1 therapies.
- Commercial Viability
- The pace at which Rose Pharma advances ROSE-010 toward late-stage development and potential partnerships.